Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ReACp53 |
Synonyms | |
Therapy Description |
ReACp53 is a peptide that inhibits Tp53 aggregation, resulting in reactivation of Tp53 pathway signaling in Tp53-mutant cells, and potentially resulting in increased tumor cell death (PMID: 26748848, PMID: 31471556) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ReACp53 | p53 Activator 11 | ReACp53 is a peptide that inhibits Tp53 aggregation, resulting in reactivation of Tp53 pathway signaling in Tp53-mutant cells, and potentially resulting in increased tumor cell death (PMID: 26748848, PMID: 31471556) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 R175H | head and neck cancer | sensitive | ReACp53 | Preclinical | Actionable | In a preclinical study, ReACp53 induced cell death and decreased proliferation of head and neck carcinoma cells harboring TP53 R175H in culture (PMID: 26748848). | 26748848 |
TP53 loss | ovarian cancer | no benefit | ReACp53 | Preclinical | Actionable | In a preclincial study, ReACp53 did not induce cell death in ovarian cancer cells with loss of TP53 in culture (PMID: 26748848). | 26748848 |
TP53 Y327L | ovarian carcinoma | sensitive | ReACp53 | Preclinical | Actionable | In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y327L in culture (PMID: 26748848). | 26748848 |
TP53 inact mut | ovarian carcinoma | sensitive | ReACp53 | Preclinical | Actionable | In a preclinical study, ReACp53 induced cell death and decreased proliferation of ovarian carcinoma cells harboring TP53 mutations in culture, but did not effect viability of ovarian carcinoma cells with wild-type TP53 (PMID: 26748848). | 26748848 |
TP53 Y234C | ovarian carcinoma | sensitive | ReACp53 | Preclinical | Actionable | In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y234C in culture (PMID: 26748848). | 26748848 |
TP53 R175H | Advanced Solid Tumor | sensitive | ReACp53 | Preclinical | Actionable | In a preclinical study, treatment with ReACp53 induced cell death in primary human uterine fibroblasts expressing TP53 R175H in culture (PMID: 26748848). | 26748848 |
TP53 R248Q | ovarian cancer | sensitive | ReACp53 | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, ReACp53 rescued p53 activity and decreased viability of ovarian cancer cells harboring TP53 R248Q in culture, and induced tumor regression in patient-derived ovarian cancer xenograft models harboring TP53 R248Q (PMID: 26748848). | 26748848 |
TP53 I195* TP53 R248Q | ovarian carcinoma | sensitive | ReACp53 | Preclinical | Actionable | In a preclinical study, ReACp53 induced cell death and decreased proliferation of human primary ovarian carcinoma cells harboring both TP53 I195* and TP53 R248Q in culture (PMID: 26748848). | 26748848 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|